Phagocytosis-shielded lentiviral vectors improve liver gene therapy in nonhuman primates.
Ontology highlight
ABSTRACT: Liver-directed gene therapy for the coagulation disorder hemophilia showed safe and effective results in clinical trials using adeno-associated viral vectors to replace a functional coagulation factor, although some unmet needs remain. Lentiviral vectors (LVs) may address some of these hurdles because of their potential for stable expression and the low prevalence of preexisting viral immunity in humans. However, systemic LV administration to hemophilic dogs was associated to mild acute toxicity and low efficacy at the administered doses. Here, exploiting intravital microscopy and LV surface engineering, we report a major role of the human phagocytosis inhibitor CD47, incorporated into LV cell membrane, in protecting LVs from uptake by professional phagocytes and innate immune sensing, thu
SUBMITTER: Milani M
PROVIDER: S-EPMC7613847 | biostudies-literature | 2019 May
REPOSITORIES: biostudies-literature
ACCESS DATA